# Open-label, Extension Study of CDP870 in Patients With Rheumatoid Arthritis

> **NCT01197066** · PHASE3 · COMPLETED · sponsor: **Korea Otsuka Pharmaceutical Co., Ltd.** · enrollment: 110 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Certolizumab Pegol

## Key facts

- **NCT ID:** NCT01197066
- **Lead sponsor:** Korea Otsuka Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2016-11
- **Final completion:** 2016-11
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2022-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01197066

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01197066, "Open-label, Extension Study of CDP870 in Patients With Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT01197066. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*